Skip to main content

Alexion.US

This site is intended for US audiences. If you are in another region, please visit our global site to learn more or be directed to your local country page.

Hypophosphatasia (HPP)

What is HPP?

HPP is a rare, inherited and progressive metabolic disease characterized by defective mineralization (the process that hardens and strengthens bones and teeth), impaired calcium and phosphate regulation and non-skeletal manifestations, such as muscle weakness, generalized fatigue and pain.1-3

HPP is caused by deficient activity of an enzyme known as alkaline phosphatase (ALP), which is important for building healthy bones as well as proper function of muscles. When ALP is functioning normally, it allows calcium and phosphate to bind together to form healthy, strong bones.1

HPP Symptoms

Signs and symptoms may vary and can impact many different parts of the body, including:1-3,6-9 

Bones

Abnormally shaped head, pseudofractures, bone deformities, softening of bones, rickets*, frequent fractures, persistent musculoskeletal pain, waddling gait, enlarged wrists, knees and ankles.

Muscles and joints

Muscle weakness, neuromuscular pain, generalized body pain, joint stiffness or swelling, fatigue, arthritis, fibromyalgia.

Robs and Lungs

Ribs and lungs

Underdeveloped ribs and lungs, severe breathing difficulties*, respiratory failure*.

Central nervous system

Pain, headaches, vitamin B6-dependent seizures, brain fog, depressed mood.

Kidneys

Kidney stones, decreased kidney function.

Teeth

Early tooth loss with the root intact*, gum disease.

*Signs and symptoms in infants and/or young children.
Signs and symptoms in infants.

My hope for Tanner in the future is that he enters into adulthood. I kind of hope that he will be a doctor, and maybe help kids like doctors have helped him."

René, Mother Of Tanner

Living with HPP

Tanner, living with HPP

References

  1. Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(suppl 2):380-388.
  2. Dahir KM, Seefried L, Kishnani PS, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17(1):277.
  3. Seefried L et al. Burden of illness in adults with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry. J Bone Miner Res. 2020;35(11):2171-2178.
  4. Fang S, et al. Diagnosed prevalence of hypophosphatasia in the United States: a real-world analysis of electronic health records [poster]. Poster presented at: Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 23-27 August 2023, Halifax, Nova Scotia, Canada.
  5. Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci. 2010;1192:190-200.
  6. Weber TJ, et al. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65(10):1522-1530.
  7. Whyte MP, et al. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr. 2019;209(4):116-124.
  8. Beck C, et al. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int. 2011;31(10):1315-1320.
  9. Khan AA, et al. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024;35(3):431-438.

Veeva ID: US/UNB-H/0665